As Medpundit points out, sometimes, unfortunately, the thought process with pharmaceutical company-sponsored studies is like that: “well, we did the study, how can we spin the results now?”

I am not saying that this is the case with the recently publicized research that Avandia “cut the risk of developing Type 2 diabetes by more than half” but at least one doctor has doubts: “It is giving the impression that

it prevents diabetes, when really what it is doing is delaying the diagnosis for one year,” said Dr. Jim Wright, managing director of the B.C. Therapeutics Initiative.”

Update 05/21/2007:
Avandia (Rosiglitazone) May Increase Risk of Cardiovascular Death

References:
Let Us Now Praise Expensive Drugs. Medpundit.
The DREAM study, Are we preventing or just delaying diabetes? Retired doc’s thoughts.
Image source: Rosiglitazone, from Wikipedia, the free encyclopedia.

Original post by Clinical Cases